Clinical trials: Advanced Tumor
Advanced Solid Tumor
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Objectives: To characterize safety, tolerability, MTD and OBD of intratumoral injection of SGN1 in patients with advanced solid tumors, and to preliminarily investigate the efficacy and safety of SGN1 in specific tumor subtypes.
- Trial name
- NCT05103345
- Testing
- SGN1
- Where
- 4 sites in China, Taiwan
- Volunteers
- 70 people
- Sponsor
- Guangzhou Sinogen Pharmaceutical Co., Ltd
First-line Treatment, Advanced Colorectal Cancer
Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC
This is a two-group, parallel, randomized, standard-control phase II study comparing the safety and efficacy of trifluridine/tipiracil combined with oxaliplatin and bevacizumab versus XELOX plus bevacizumab in the first-line…
- Trial name
- TOBACO (NCT05077839)
- Testing
- Trifluridine/Tipiracil
- Where
- China
- Volunteers
- 184 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Neoplasms, Lymphoma
An Early Phase I Study of IPdR Absorption, Metabolism, and Safety in Patients With Advanced Solid Tumors and Lymphomas
Background: The experimental drug IPdR is broken down in the body to IdUrd, which has been given to patients to find out if it can improve radiation therapy.
- Trial name
- NCT01240577
- Testing
- IPdR
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Triple Negative Breast Neoplasms
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. It will find out what side effects happen when participants get these two drugs.
- Trial name
- NCT03310957
- Testing
- ladiratuzumab vedotin, Pembrolizumab
- Where
- 50 sites in United States, Germany and 2 more
- Volunteers
- 185 people
- Sponsor
- Seagen Inc.
Advanced Solid Tumors
A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors
This first-in-human open-label,dose-escalation study is designed to evaluate the safety, tolerability, and primary efficacy of IBI321 in participants with locally advanced, recurrent, or metastatic incurable tumors for whom…
- Trial name
- NCT04911881
- Testing
- IBI321
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Rectal Cancer
Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer
This is a phase III randomized controlled trial comparing the efficacy and safety of FOLFOXIRI versus CapeOX as neoadjuvant regimen in treating patients with middle and upper locally advanced (MRI T3-4 or N+) rectal cancer.
- Trial name
- RCNAC (NCT05201430)
- Testing
- FOLFOXIRI, CapeOX
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Symptom Managemen, Late Stage Lung Cancer
The Impact of Symptom Management Nursing Intervention on the QoL of Patients With Advanced Lung Cancer: Mediation of Self-management Efficacy and Regulation of Psychological Resilience
Symptom management nursing intervention can improve the self-management efficacy, psychological resilience, and QoL of patients with advanced lung cancer.
- Conditions
- Symptom Managemen, Late Stage Lung Cancer, QoL, Self Management Efficacy
- Trial name
- NCT07679165
- Testing
- routine nursing group, standardized systematic SM nursing group
- Where
- China
- Volunteers
- 176 people
- Sponsor
- Jie Zeng
Solid Tumor, Advanced Solid Tumor
NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
Parts 1 and 2 The primary purpose of this study is to understand the safety of NL-201 when given intravenously as monotherapy in patients with advanced cancer to evaluate tolerability and to identify a recommended dose and…
- Trial name
- NCT04659629
- Testing
- NL-201, Pembrolizumab Injection [Keytruda]
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 59 people
- Sponsor
- Neurogene Inc.
Carcinoma, Non-Small-Cell Lung, Melanoma
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
This is a phase I/Ib, open label study. The escalation portion will characterize the safety and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer
- Trial name
- NCT03891953
- Testing
- DKY709, PDR001
- Where
- 9 sites in United States, Germany and 4 more
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma
Predictors of Sorafenib Response in HCC
Evaluating the nutrition status of patients with advanced HCC who received sorafenib. Using the pretreatment nutrition status and quality of life as predictors to sorafenib response
- Trial name
- NCT05967429
- Testing
- The neutrophil-to- lymphocyte ratio, Prognostic nutrition index
- Volunteers
- 80 people
- Sponsor
- Sohag University
Advanced Cancer, Angiosarcoma
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1…
- Conditions
- Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer
- Trial name
- NCT03860272
- Testing
- Botensilimab, Balstilimab
- Where
- 18 sites in United States, United Kingdom
- Volunteers
- 499 people
- Sponsor
- Agenus Inc.
Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC
Neoadjuvant Becotatug Vedotin Plus Pucotenlimab and Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma
This clinical trial aims to evaluate the efficacy and safety of Becotatug Vedotin (EGFR-Targeting ADC) in combination with Pucotenlimab and Cisplatin as neoadjuvant therapy for patients with locally advanced head and neck…
- Trial name
- NCT07393477
- Testing
- Combination Therapy with Becotatug Vedotin, Pucotenlimab, and Cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sir Run Run Shaw Hospital
Cholangiocarcinoma
Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma
This study aims to validate the efficacy and safety of GP/GEMOX combined with PD-1/L1 inhibitors and TKI agents in patients with advanced cholangiocarcinoma through a multicenter, retrospective study to guide clinical practice.
- Trial name
- NCT06718257
- Testing
- Gemcitabine combined with cisplatin or oxaliplatin, Gemcitabine combined with cisplatin or oxaliplatin, PD-1/L1 and TKI inhibitors
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Rectal Cancer
Conventional Versus Individual Extralvator Abdominoperineal Excision for Advanced Lower Rectal Cancer
An alternative treatment for low rectal cancer is the extralevator abdominoperineal excision (ELAPE) technique. We aim to compare the outcomes of patients undergoing conventional ELAPE versus Individual ELAPE.
- Trial name
- ELAPE (NCT02036112)
- Testing
- conventional ELAPE, Individual ELAPE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Chao Yang Hospital
Metastatic Tumor, Renal Cell Carcinoma
Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with advanced/metastatic renal cell carcinoma, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
- Conditions
- Metastatic Tumor, Renal Cell Carcinoma, Advanced Cancer
- Trial name
- NCT05420519
- Testing
- CD70 CAR-T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Advanced Malignant Solid Tumours
A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour
This study is a Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects with Advanced Malignant Solid Tumour.
- Trial name
- NCT06888830
- Testing
- JS212 for Injection
- Where
- China
- Volunteers
- 374 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Gastric Cancer, Hepatocellular Carcinoma
Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer
The purpose of this study is to observe and preliminary explore the efficacy and safety of combination of Apatinib and SHR-1210 regimen in treating advanced hepatocellular carcinoma or gastric cancer.
- Trial name
- NCT02942329
- Testing
- apatinib, SHR-1210
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Exercise, Total Neoadjuvant Treatment
Study of Daily Step Count and Treatment Response in Rectal Cancer (STEP-R)
This study aims to examine the impact of daily physical activity, specifically step count, on treatment outcomes and side effects in patients with locally advanced rectal cancer receiving total neoadjuvant therapy (chemotherapy…
- Conditions
- Exercise, Total Neoadjuvant Treatment, Rectal Tumors, Smart Watch
- Trial name
- STEP-R (NCT06668402)
- Testing
- Utilizing a smartwatch to gather data on individuals receiving treatment for rectal neoplasm.
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 160 people
- Sponsor
- Gazi University
Advanced Solid Tumors or Lymphomas
A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas
CA-170 is a rationally designed and orally available, small molecule that directly targets the Programmed death-ligands 1 and 2 (PD-L1/PD-L2), and V-domain Ig suppressor of T cell activation (VISTA) immune checkpoints and results…
- Trial name
- NCT02812875
- Testing
- CA-170
- Where
- 20 sites in United States, South Korea and 2 more
- Volunteers
- 71 people
- Sponsor
- Curis, Inc.
Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma
Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
Background: Oral hedgehog inhibitors vismodegib and sonidegib have been used for the treatment of locally advanced (laBCC), metastatic basal cell carcinoma (mBCC) and in basal cell nevus syndrome (BCNS) patients.
- Conditions
- Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma, Metastatic Basal Cell Carcinoma, Gorlin Syndrome
- Trial name
- NCT05463757
- Testing
- Vismodegib, Sonidegib
- Where
- 8 sites in Netherlands
- Volunteers
- 80 people
- Sponsor
- Maastricht University Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.